logo

For the Inventor, By the Inventor

Shelton, CT, United States of America

Cara Therapeutics, Inc.


USPTO Granted Patents = 31

% Expired Patents = 3.2



Trademarks = 3

Forward Citations = 587

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Claudio Daniel Schteingart (17 out of 27 patents)

silverMedal Frédérique Menzaghi (16 out of 19 patents)

bronzeMedal Guangcheng Jiang (16 out of 26 patents)

4.  Roberta Vezza Alexander (16 out of 17 patents)

5.  Javier Sueiras-Diaz (16 out of 19 patents)

6.  Derek T Chalmers (16 out of 37 patents)

7.  Robert H Spencer (15 out of 17 patents)

8.  Zhiyong Luo (13 out of 13 patents)

9.  Robert Zhiyong Luo (10 out of 15 patents)

10.  Gary Gustafson (6 out of 45 patents)

11.  Stephen J O'Connor (5 out of 26 patents)

12.  R Paul Beckett (4 out of 4 patents)

13.  Carla M Gauss (4 out of 4 patents)

14.  Janet L Ralbovsky (4 out of 9 patents)

15.  Tatiana Shelekhin (3 out of 24 patents)


Core Competencies:
Kappa Opioid Receptor
Synthetic Peptide Amides
Pain Management
Oligosaccharide Formulations
Oral Formulations
Imidazoheterocycles
Bicyclic Pyrazolo-Heterocycles
Dimeric Forms
Substituted Pyridoxazines
Benzo-Fused Heterocycles

31 patents:

1. 11986509 - Oligosaccharide formulations of kappa opioid receptor agonists (2024-05-21),
2. 11684674 - Oral formulations of kappa opioid receptor agonists (2023-06-27),
3. 11033629 - Oral formulations of kappa opioid receptor agonists (2021-06-15),
4. 10913769 - Synthetic peptide amides and dimers thereof (2021-02-09),
5. 10793596 - Synthetic peptide amides (2020-10-06),
6. 10138270 - Synthetic peptide amides (2018-11-27),
7. 10017536 - Synthetic peptide amides and dimers thereof (2018-07-10),
8. 9359399 - Synthetic peptide amides (2016-06-07),
9. 9334305 - Synthetic peptide amides and dimers thereof (2016-05-10),
10. 9321810 - Uses of kappa opioid synthetic peptide amides (2016-04-26),
11. 8951970 - Synthetic peptide amides for pain (2015-02-10),
12. 8859538 - Uses of substituted imidazoheterocycles (2014-10-14),
13. 8835422 - Substituted imidazoheterocycle derivatives (2014-09-16),
14. 8669079 - [object Object] (2014-03-11),
15. 8653127 - Bicyclic pyrazolo-heterocycles (2014-02-18),
Company Overview
Cara Therapeutics, Inc. is a biopharmaceutical company based in Shelton, Connecticut, focused on developing innovative therapies for pain and pruritus. The company specializes in creating novel treatments that target the body's kappa opioid receptor system, aiming to provide safer and more effective options for patients suffering from chronic conditions. Cara Therapeutics is committed to advancing its research in the field of pain management and dermatology, striving to improve the quality of life for individuals affected by these challenging health issues.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Cara Therapeutics, Inc. USPTO Patent Assignee Logo
31 Patents

#13 in Shelton, CT

#282 in Connecticut

#10,927 in US

#21,260 in the World

Shelton, CT (US)
Shelton, CT, United States of America

Cara Therapeutics, Inc.

Forward Citations = 587

28 inventors:

goldMedal Claudio Daniel Schteingart (17 out of 27 patents)

silverMedal Frédérique Menzaghi (16 out of 19 patents)

bronzeMedal Guangcheng Jiang (16 out of 26 patents)

4.  Roberta Vezza Alexander (16 out of 17 patents)

5.  Javier Sueiras-Diaz (16 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cara Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cara-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…